PHILADELPHIA, May 28, 2014 /PRNewswire/ -- Premier Research today announced the appointment of Martin Nicklasson, Ph.D., to its board of directors.
Nicklasson brings to Premier Research a wealth of international experience in the biopharmaceutical sector, both at the executive and at the board level. A native of Sweden with a doctoral degree from the University of Uppsala, Nicklasson held positions in pharmaceutical development, R&D management, and global marketing, as well as franchise management in Astra, Kabi Pharmacia, and AstraZeneca. He became the CEO of AstraZeneca (Sweden) before moving on to the biotechnology sector as the CEO of Biovitrum.
Upon his retirement from Biovitrum, he founded Nicklasson Life Science to support the growth and development of a series of biotechnology and specialty pharmaceutical companies, either as non-executive director or as chairman. Currently, Nicklasson chairs the board of directors of Basilea Pharmaceuticals, Orexo AB, and Farma Holdings AS; he is a non-executive director of Biocrine AB, Pozen Inc., and Oasmia AB.
"The appointment of a respected leader like Dr. Nicklasson to our board strengthens the company's ability to identify and evaluate the rapidly changing needs in the management of biopharmaceutical R&D," Premier Research CEO & President Dr. Ludo Reynders said. "As the company continues to target sectors of unmet needs in clinical development from a clinical, regulatory, or customer perspective, Martin's advice and judgment will be invaluable in setting and following the course."
About Premier Research
Premier Research is a leading contract research organization serving the needs of biotechnology, pharmaceutical, and medical device companies worldwide. The company has a wealth of experience in the execution of global, regional, and local clinical development programs with a special focus on addressing unmet needs in such areas as analgesia, CNS, rare diseases, medical device and diagnostics, and pediatric research. Premier Research operates in 50 countries and employs more than 1,000 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. With its mission to improve productivity in clinical development, the company aligns itself with the mission of its customers to bring new medical treatments to patients promptly, accurately, and cost-effectively. Visit Premier Research at: www.premier-research.com
SOURCE Premier Research